210
Participants
Start Date
July 31, 2013
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Brexpiprazole
1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
US010, Anaheim
US020, Cerritos
US009, Escondido
US022, Garden Grove
US018, Long Beach
US011, San Diego
US021, Washington D.C.
US004, Kissimmee
US015, North Miami
US019, Lake Charles
US016, St Louis
US002, Cedarhurst
US005, Charleston
US003, Austin
US012, Austin
US001, Dallas
US013, Dallas
EE002, Pärnu
EE001, Tallinn
PL002, Choroszcz
PL005, Choroszcz
PL004, Gdansk
RO004, Brasov
RO007, Bucharest
RO011, Bucharest
RO012, Bucharest
RO010, Iași
RO006, Piteşti
RU001, Arkhangelsk
RU008, Moscow
RU015, Rostov-on-Don
RU004, Saint Petersburg
RU005, Saint Petersburg
RU013, Saint Petersburg
RU002, Saratov
RS001, Belgrade
RS003, Belgrade
RS002, Kragujevac
RS004, Novi Kneževac
SK001, Liptovský Mikuláš
UA012, Dnipropetrovsk
UA004, Geikivka
UA007, Hlevakha
UA005, Kherson
UA008, Kyiv
UA009, Lviv
UA002, Smila
UA003, Vinnytsia
Collaborators (1)
Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
H. Lundbeck A/S
INDUSTRY